Nelfinavir mesylate AG1343
Categoria
Nelfinavir mesylate AG1343 Nombres de marca, Nelfinavir mesylate AG1343 Analogos
Nelfinavir mesylate AG1343 Marca los nombres de mezcla
Nelfinavir mesylate AG1343 Formula quimica
C32H45N3O4S
Nelfinavir mesylate AG1343 RX enlace
http://www.rxlist.com/cgi/generic2/nelfin.htm
Nelfinavir mesylate AG1343 FDA hoja
Nelfinavir mesylate AG1343 MSDS (hoja de seguridad de materiales)
Nelfinavir mesylate AG1343 Sintesis de referencia
No hay información disponible
Nelfinavir mesylate AG1343 Peso molecular
567.784 g/mol
Nelfinavir mesylate AG1343 Punto de fusion
349.84 oC
Nelfinavir mesylate AG1343 H2O Solubilidad
Ligeramente soluble
Nelfinavir mesylate AG1343 Estado
Solid
Nelfinavir mesylate AG1343 LogP
5.247
Nelfinavir mesylate AG1343 Formas de dosificacion
Tablet (oral - 250 mg, 625 mg) en polvo (oral)
Nelfinavir mesylate AG1343 Indicacion
Nelfinavir mesylate AG1343 Farmacologia
Nelfinavir es un inhibidor de la proteasa con actividad contra el virus de inmunodeficiencia humana tipo 1 (VIH-1). Inhibidores de la proteasa bloquean la parte del VIH llamada proteasa. VIH-1 proteasa es una enzima necesaria para la enzima. Esta inhibición impide la división de las poliproteínas viral que resulta en la formación de inmaduros no partículas virales infecciosas. Inhibidores de la proteasa se utilizan casi siempre en combinación
Nelfinavir mesylate AG1343 Absorcion
Se absorbe bien tras la administración oral.
Nelfinavir mesylate AG1343 Toxicidad
DL50 oral es más 5g/kg en ratas. Los efectos secundarios incluyen la sed y el hambre, la pérdida de peso inexplicable, aumento de la orina, fatiga, piel seca, picazón.
Nelfinavir mesylate AG1343 Informacion de Pacientes
PATIENT INFORMATION
Patients should be informed that VIRACEPT is not a cure for HIV infection and that they may
continue to acquire illnesses associated with advanced HIV infection, including opportunistic
infections.
Patients should be told that the long-term effects of VIRACEPT are unknown at this time. They
should be told that there is currently no data demonstrating that VIRACEPT therapy can reduce
the risk of transmitting HIV to others through sexual contact or blood contamination.
Patients should be advised to take VIRACEPT every day as prescribed. Patients should not alter
the dose or discontinue therapy without consulting with their doctor. If a dose is missed, patients
should take the dose as soon as possible and then return to their normal schedule. However, if a dose
is skipped, the patient should not double the next dose.
The most frequent adverse event associated with VIRACEPT is diarrhea, which can usually be controlled
with non-prescription drugs, such as loperamide, which slow gastrointestinal motility.
VIRACEPT may interact with some drugs, therefore, patients should be advised to report to their doctor
the use of any other prescription or non-prescription medication.
Patients receiving oral contraceptives should be instructed that alternate or additional contraceptive
measures should be used during therapy with VIRACEPT.
Patients should be informed that VIRACEPT is not a cure for HIV infection and that they may
continue to acquire illnesses associated with advanced HIV infection, including opportunistic
infections.
Patients should be told that the long-term effects of VIRACEPT are unknown at this time. They
should be told that there is currently no data demonstrating that VIRACEPT therapy can reduce
the risk of transmitting HIV to others through sexual contact or blood contamination.
Patients should be advised to take VIRACEPT every day as prescribed. Patients should not alter
the dose or discontinue therapy without consulting with their doctor. If a dose is missed, patients
should take the dose as soon as possible and then return to their normal schedule. However, if a dose
is skipped, the patient should not double the next dose.
The most frequent adverse event associated with VIRACEPT is diarrhea, which can usually be controlled
with non-prescription drugs, such as loperamide, which slow gastrointestinal motility.
VIRACEPT may interact with some drugs, therefore, patients should be advised to report to their doctor
the use of any other prescription or non-prescription medication.
Patients receiving oral contraceptives should be instructed that alternate or additional contraceptive
measures should be used during therapy with VIRACEPT.
Nelfinavir mesylate AG1343 Organismos afectados
Virus de inmunodeficiencia humana
